Solutions · Market Access
Turn approval into access, before the market moves without you
pharcel maps every payer, closes your evidence gaps, and assembles the value dossiers and HTA submissions that win reimbursement, so your therapy reaches patients months sooner.
The challenge
Access teams fight for reimbursement with fragmented evidence
18 mo
from launch to broad reimbursement
Value dossiers, HTA submissions, and payer negotiations move sequentially through consultants and agencies, delaying access long after approval.
Siloed
evidence across teams
HEOR studies, real-world evidence, and published outcomes sit in separate repositories that no access lead can query in one place.
Reactive
pricing intelligence
Reimbursement decisions, tender outcomes, and comparator pricing surface weeks late, so teams respond to the market instead of shaping it.
What pharcel does
One platform for the entire access and reimbursement journey
Payer Landscape Mapping
Map every national and regional payer, HTA body, and decision pathway for your indication, coverage criteria, evidence thresholds, and timelines, in one continuously updated view.
Evidence Generation (HEOR / RWE)
Identify evidence gaps against payer requirements and orchestrate the HEOR and real-world studies that close them, tied directly to the objections each payer raises.
Formulary & Tender Intelligence
Track formulary positions, tender cycles, and award outcomes across markets, so your team enters every negotiation knowing where you stand versus every comparator.
Value Dossier Automation
Assemble AMCP, GVD, and country value dossiers from your evidence base with citations intact, drafted in days, kept current as new data lands.
Pricing & Reimbursement Tracking
Monitor list and net price movements, reimbursement rulings, and reference-pricing changes across markets before they cascade into your portfolio.
HTA Submission Support
Model the economic case, align evidence to each agency's methods guide, and pressure-test your submission against likely HTA critique before you file.
The outcome
40%
faster value dossier turnaround
6 mo
pulled forward on reimbursement timelines
1 view
unifying evidence, payers, and pricing
100%
of HTA objections mapped to evidence
How it works
Access-ready in weeks, not the next submission window
01
Connect your evidence
Link your HEOR library, RWE datasets, published literature, and pricing feeds. pharcel unifies them into a single access graph, no manual dossier hunting required.
02
Deploy the agents
Payer-mapping, evidence-gap, and dossier agents run against your live data, surfacing every objection, gap, and pricing signal for your team to review and approve.
03
Submit with confidence
Approved dossiers, submission packages, and payer strategies flow to your access and HTA teams, aligned to each agency's requirements from the first draft.
“We used to learn a payer's objection only after they rejected us. With pharcel we walk into every HTA meeting already knowing the gap, and the evidence that closes it.”
VP Market Access · Global Specialty Pharma
Powered by these modules
See pharcel run on your access strategy
Book a demo and we will map the payer landscape, evidence gaps, and dossier requirements for your own indication and markets.
Request a Demo